Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study
Authors' conclusion
MTX, as well as other synthetic immunosuppressants, showed limited efficacy in ASS-related arthritis, while RTX emerged as a promising option.
Study context
- Population
- Patients with anti-synthetase syndrome (ASS) referred to a multidisciplinary Myositis Clinic
- Participants
- 27 patients
- Outcome
- Disease activity/remission by domain (arthritis, myositis, ILD) and PDN discontinuation
- Follow-up
- 12 months
Methodological detailspilot study, single-group, step-down treatment protocol, Data collected at baseline, 6 and 12 months, Arthritis, myositis and ILD assessed in 9, 16 and 18 patients, respectively; all with active disease
- Pilot study
- Single-group
- Step-down treatment protocol
- Data collected at baseline, 6 and 12 months
- Arthritis, myositis and ILD assessed in 9, 16 and 18 patients, respectively; all with active disease
Main finding
As reported in the abstract
- Refractory joint involvement: Rituximab (RTX) given after methotrexate (MTX)
- 4
- Arthritis: second immunosuppressant co-administration necessary
- 2
- ILD: treated with mycophenolate mofetil (MMF)
- 8
- ILD: switched to RTX for inefficacy
- 5
- Discontinued prednisone (PDN) at 12 months
- 12
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study. Semin Arthritis Rheum. Published 24 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →